BMS Global Value Pack User Survey

Thank you in advance for providing your feedback to support the development of the HCV Global Value Pack

Please read the following instructions:

• This survey should take you approximately 5 minutes to complete.
• Please note that the entire survey will be conducted on a strictly confidential basis; your answers will be reported in aggregate with others participating in this survey.

* 1. Which of the following best describes your working group? Please select one only.

* 2. What are your main geographies of focus? Please select all that apply.

3. On a scale of 1 – 5, where 1 is very little knowledge and 5 is very high knowledge, please rate your knowledge of hepatitis C (HCV) below. Please note: HCV knowledge could be specific to your role or general. Please select one only.

* 4. Overall, what proportion of your time do you estimate will be spent on HCV-related activities in second half of 2013? Please indicate in the spaces below.

5. The table below lists the planned HCV Global Value Pack modules and contents. The GVP contents are global in nature and will provide training on a global scale. Next to each content item, please select "likely" if you are likely to use the item in your work or select "Not likely" if you are not likely to use the GVP content item in your work. If the item does not apply to your work, please select "not applicable." Please select one only for each item.

	Likely	Not Likely	Not Applicable
Intro to disease and current treatments

Burden of disease

Epidemiology

Unmet need

Treatment guidelines

Access landscape

Review of HTA assessments of HCV products

Competitor environment strategy and launch timelines

Clinical plan / Clinical data

Comparator clinical trials including Indirect Comparisons

	Likely	Not Likely	Not Applicable
Comparator economic assessments

Access strategy

Value story

Training on dossier structure

Core dossier

Communication toolkit including value messages on burden of disease

Payer partnerships guidance

Contracting options guidance

Guidance to markets re: influencing treatment guidelines for HCV

Communication toolkit including value messages on DCV/ASV

	Likely	Not Likely	Not Applicable
Negotiation guide

Payer vis aid

Budget impact model slide deck

Cost-effectiveness model slide deck

Guidance for local adaptation budget impact model

Guidance for local adaptation cost-effectiveness model

Timeline for final model roll-out/Adaptation

BIM model for adaptation

CE model for adaptation

* 6. Are there any items you would like to see included in the GVP that are not included in the table above? Please select one only.

No

Yes (please list any additional items you would like included in the HCV GVP in the text box below.)

7. To ensure the timing of the HCV GVP launch fits users’ needs, please indicate the timing of the completion of following activities in terms of months prior to marketing approval, if applicable to your position. Please select one only for each activity to indicate when the activity is completed in terms of months prior to marketing approval.

8. Considering your launch planning, when would you like to have access to the finalized version 1 of the HCV Global Value Pack contents? Please note Phase III data is not expected to be available until 1Q2014. The final version of the HCV GVP will be developed after Phase III data is available. Please select one only.

9. In your opinion, what is the best approach to preparing the HCV GVP contents? Please select one only.

Approach by asset (e.g. materials focus mainly on the products themselves, for example, daclatasvir or asunaprevir)

Approach by regimen (e.g. materials focus mainly on the regimens DCV+ASV DUAL)

Blend of both (daclatasvir and associated regimen options)